guest ::
| Home > Publications database > Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer. > print |
| Home > Publications database > Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer. > print |
| 001 | 274148 | ||
| 005 | 20240229154927.0 | ||
| 024 | 7 | _ | |a 10.1002/hed.27298 |2 doi |
| 024 | 7 | _ | |a pmid:36872620 |2 pmid |
| 024 | 7 | _ | |a 0148-6403 |2 ISSN |
| 024 | 7 | _ | |a 1043-3074 |2 ISSN |
| 024 | 7 | _ | |a 1097-0347 |2 ISSN |
| 024 | 7 | _ | |a 1930-2398 |2 ISSN |
| 024 | 7 | _ | |a altmetric:143237539 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00458 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Regnery, Sebastian |b 0 |
| 245 | _ | _ | |a Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer. |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2023 |b Wiley Interscience |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1687854407_19594 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:E055# / 2023 Apr;45(4):838-848 |
| 520 | _ | _ | |a We aimed to demonstrate the effects of tumor treating fields (TTFields) in head and neck squamous cell carcinoma (HNSCC) cells when combined with radiotherapy (RT) and chemotherapy.Two human HNSCC cell lines (Cal27, FaDu) received five different treatments: TTFields, RT +/- TTFields and RT + simultaneous cisplatin +/- TTFields. Effects were quantified using clonogenic assays and flow cytometric analyses of DAPI, caspase-3 activation and γH2AX foci.Treatment with RT + TTFields decreased the clonogenic survival as strong as treatment with RT + simultaneous cisplatin. The triple combination of RT + simultaneous cisplatin + TTFields even further decreased the clonogenic survival. Accordingly, combination of TTFields with RT or RT + simultaneous cisplatin increased cellular apoptosis and DNA double-strand breaks.TTFields therapy seems a promising combination partner in the multimodal treatment of locally advanced HNSCC. It could be used to intensify chemoradiotherapy or as alternative to chemotherapy. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a chemoradiotherapy |2 Other |
| 650 | _ | 7 | |a head and neck cancer |2 Other |
| 650 | _ | 7 | |a radiotherapy |2 Other |
| 650 | _ | 7 | |a squamous cell carcinoma of head and neck |2 Other |
| 650 | _ | 7 | |a tumor treating fields |2 Other |
| 700 | 1 | _ | |a Franke, Henrik |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Held, Thomas |0 P:(DE-He78)cbbd83b83a83176c38ba2c45ac072a3d |b 2 |
| 700 | 1 | _ | |a Trinh, Thuy |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Naveh, Ariel |b 4 |
| 700 | 1 | _ | |a Abraham, Yissachar |b 5 |
| 700 | 1 | _ | |a Hörner-Rieber, Juliane |0 P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0 |b 6 |u dkfz |
| 700 | 1 | _ | |a Hess, Jochen |0 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f |b 7 |u dkfz |
| 700 | 1 | _ | |a Huber, Peter |0 P:(DE-He78)3291aaac20f3d603d96744c1f0890028 |b 8 |u dkfz |
| 700 | 1 | _ | |a Debus, Jürgen |0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |b 9 |u dkfz |
| 700 | 1 | _ | |a Lopez Perez, Ramon |0 P:(DE-He78)c5a1a98649a7874de0def093eb136262 |b 10 |u dkfz |
| 700 | 1 | _ | |a Adeberg, Sebastian |0 0000-0001-8463-514X |b 11 |e Last author |
| 773 | _ | _ | |a 10.1002/hed.27298 |g p. hed.27298 |0 PERI:(DE-600)2001440-5 |n 4 |p 838-848 |t Head & neck |v 45 |y 2023 |x 0148-6403 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:274148 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)cbbd83b83a83176c38ba2c45ac072a3d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)3291aaac20f3d603d96744c1f0890028 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)c5a1a98649a7874de0def093eb136262 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 0000-0001-8463-514X |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2022-11-16 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-16 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-16 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-08-26 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-26 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HEAD NECK-J SCI SPEC : 2022 |d 2023-08-26 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-26 |
| 920 | 2 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E221-20160331 |k E221 |l Molekulare Grundlagen von HNO-Tumoren |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E055-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E221-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|